Quotient Sciences 2025 ESG Report
3 August 20262025 has been another year of meaningful progress for Quotient Sciences. As an integrated drug development and manufacturing accelerator, our purpose is to help our partners bring new medicines to patients faster and more efficiently.
Through our Translational Pharmaceutics® platform, reducing development timelines also reduces resource use, helping to minimise material consumption, energy demand and associated carbon emissions.
This year we took a significant step towards that purpose through our collaboration with Intrepid Labs, using their machine learning platform to support AI-guided formulation development. Combined with our Translational Pharmaceutics® platform, this gives us the ability to explore formulation options more rapidly, use less drug substance in early development, and shorten development timelines — ultimately bringing new treatments to patients more quickly and efficiently.
Our environmental performance reflects sustained effort and commitment. Our total greenhouse gas footprint fell to 17,610 tCO₂e — a 13% reduction from 2024. This improvement was supported by enhanced data granularity, improved data quality and a continued shift towards a more accurate emissions inventory, with 90% now based on actual data (up from 81.2% last year). As a result, our 2025 figures represent our most comprehensive and credible emissions inventory to date.
Together, we are building a more sustainable, inclusive, and resilient future. Find out more about our ESG commitments.
